New DNA test could spot leukemia resistance earlier
NCT ID NCT07158294
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study will test whether a highly sensitive genetic test called digital PCR can detect drug-resistant mutations in people with chronic myeloid leukemia (CML) as well as the current standard method. Researchers will analyze blood samples from 150 adults with CML whose current treatment is not working well. If digital PCR proves effective, it could help doctors switch therapies faster and more accurately.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could provide a faster, more sensitive way to detect drug-resistant mutations in CML patients, helping doctors choose the right treatment sooner.
- What could go wrong
- This is an early-stage diagnostic study, not a treatment trial. The new method may not prove as reliable as existing tests, and results may not change patient outcomes directly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA (CML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New blood marker duo could spot leukemia earlier
- Could a diabetes drug help leukemia patients stay off cancer pills?
- Personalized exercise shows promise for fatigue in rare blood cancers
- Engineered donor cells aim to beat blood cancer without severe side effects
- Could dead donors provide Life-Saving bone marrow?
- Can patients stop Anti-Rejection drugs sooner after transplant?